Dr. Michael Gorin

Dr. Michael Gorin
Michael A. Gorin, M.D. is a urologist within the Milton and Carroll Petrie Department of Urology at the Icahn School of Medicine at Mount Sinai. Dr. Gorin cares for patients with a range of urologic conditions, including enlarged prostate symptoms, kidney stones, kidney tumors, and prostate cancer. As a fellowship-trained endourologist, Dr. Gorin offers patients the most advanced minimally invasive treatment options. Dr. Gorin currently sees patients at locations on Long Island and in New York City. In addition to being a skilled surgeon, Dr. Gorin is also an accomplished clinical researcher. He is widely recognized for his work studying the use of molecular imaging in the diagnosis and management of urologic malignancies. To his credit, Dr. Gorin was part of the first clinical team to study PSMA-targeted PET imaging of prostate cancer with PYLARIFY (18F-DCFPyL). Additionally, he played an integral role in the design and conduct of two multicenter clinical trials that led to the approval of this novel PET radiotracer by the United States Food and Drug Administration. Since its approval in May 2021, PYLARIFY has been used to image tens of thousands of men with prostate cancer. Dr. Gorin has also made significant contributions to the field of urology through his research on prostate cancer screening, active surveillance, and focal therapy. Notably, Dr. Gorin was one of the first urologists in the United States to perform MRI-guided prostate biopsy using the transperineal approach. He is responsible for generating much of the clinical data supporting this safer and more accurate method of prostate biopsy. Dr. Gorin frequently gives invited talks on his work in this arena and proctors other urologists learning to perform the diagnostic techniques he has helped pioneer. To date, Dr. Gorin has published over 300 articles in peer-reviewed journals with collaborators from around the world. Additionally, he has contributed to multiple medical textbooks, including chapters in Campbell-Walsh-Wein Urology, The 5-Minute Urology Consult, and Gray's Anatomy. In July 2022, Dr. Gorin was named Editor-in-Chief of BJUI Compass, the open-access companion journal to the British Journal of Urology International. Dr. Gorin also serves on the editorial boards of several other journals, including UROLOGY (the Gold Journal), Urologic Oncology, and the World Journal of Urology. Dr. Gorin has received numerous honors and awards for his scholarly work, including the Drs. Carl and Barbara Alving Endowed Award for Outstanding Biomedical Research from the University of Miami Miller School of Medicine and the William F. Rienhoff, Jr., M.D. Scholar Award from Johns Hopkins University School of Medicine. Dr. Gorin attended college at the University of Michigan, earning a Bachelor of Science in Cellular and Molecular Biology. He then attended medical school at the University of Miami Leonard M. Miller School of Medicine, where he graduated as an inductee to the Alpha Omega Alpha Honor Medical Society. Following medical school, Dr. Gorin completed a general surgery internship, urology residency, and fellowship in endoscopic and minimally invasive urology at the world-renowned James Buchanan Brady Urological Institute at Johns Hopkins University School of Medicine.
Medical School:

University of Miami Leonard M. Miller School of Medicine, Miami, FL

Residency:

Johns Hopkins University School of Medicine, Baltimore, MD

Fellowship:

Johns Hopkins University School of Medicine, Baltimore, MD

Undergraduate:

University of Michigan, Ann Arbor, MI

All surgical treatments have inherent and associated side effects. Individual’s outcomes may depend on a number of factors, including but not limited to patient characteristics, disease characteristics and/or surgeon experience. The most common side effects are mild and transient and may include mild pain or difficulty when urinating, discomfort in the pelvis, blood in the urine, inability to empty the bladder or a frequent and/or urgent need to urinate, and bladder or urinary tract infection. Other risks include ejaculatory dysfunction and a low risk of injury to the urethra or rectum where the devices gain access to the body for treatment. Further, there may be other risks as in other urological surgery, such as anesthesia risk or the risk of infection, including the potential transmission of blood borne pathogens. For more information about potential side effects and risks associated with Aquablation therapy for Benign Prostatic Hyperplasia (BPH) treatment, speak with your urologist or surgeon. Prior to using our products, please review the Instructions for Use, Operator’s Manual or User Manual, as applicable, and any accompanying documentation for a complete listing of indications, contraindications, warnings, precautions and potential adverse events. No claim is made that the AquaBeam Robotic System will cure any medical condition, or entirely eliminate the diseased entity. Repeated treatment or alternative therapies may sometimes be required.

Rx Only